Form 4: Voyager Therapeutics CFO Acquires 80,000 Shares in Inducement Grant

Nathan D. Jorgensen, CFO of Voyager Therapeutics, acquired 80,000 shares of common stock through a restricted stock unit (RSU) award as an inducement for employment.

Summary

• Nathan D. Jorgensen, the Chief Financial Officer of Voyager Therapeutics, Inc., filed a Form 4 on October 2, 2024.
• The filing reports a transaction that occurred on October 1, 2024, where Jorgensen acquired 80,000 shares of Voyager Therapeutics common stock.
• These shares were obtained through a restricted stock unit (RSU) award.
• The RSU award was granted as an inducement material to Jorgensen entering into employment with the company, in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4).
• The vesting commencement date of the RSU award is October 1, 2024.
• The RSU award vests over three years, with 1/3rd of the shares vesting on the one-year anniversary and the remainder vesting in equal annual installments thereafter, contingent upon continued employment.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The RSU grant is a standard practice and indicates investment in leadership. The vesting schedule aligns interests.

Positives

• The inducement grant to the CFO suggests the company is investing in its leadership team.
• The vesting schedule aligns the CFO's interests with the long-term performance of the company.

Future Outlook

The vesting schedule of the RSU award indicates a three-year commitment from the CFO to the company.

Industry Context

Equity compensation, including RSU awards, is a common practice in the biotechnology industry to attract and retain key executives. This grant aligns with industry standards for incentivizing leadership.

Comparison to Industry Standards

• Many biotechnology companies use stock options and restricted stock units (RSUs) as part of their compensation packages for executives.
• Companies like Amgen, Gilead Sciences, and Biogen offer similar equity-based incentives to align executive interests with shareholder value.
• The vesting schedule of three years is a standard practice in the industry to ensure long-term commitment from the executive.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it aligns the CFO's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates